TEL AVIV, Israel, April 6, 2015 (GLOBE NEWSWIRE) -- Alcobra Ltd. (Nasdaq:ADHD), an emerging pharmaceutical company focused on the development of new medications to help patients with cognitive disorders, including Attention Deficit Hyperactivity Disorder (ADHD) and Fragile X Syndrome, today announced that corporate presentations will be provided at two conferences focused on Central Nervous System (CNS) disorders in April.
|
10th Annual Neurotech Investing & Partnering Conference |
|
Date: |
|
Tuesday, April 7 |
|
Time: |
|
3:30pm Pacific Time |
|
Location: |
|
Hotel Nikko, San Francisco |
|
Presenter: |
David Baker, Chief Commercial Officer |
|
Conference Information: |
www.neurotechconf.com |
|
|
|
|
|
Neurology Innovation Conference |
|
Date: |
|
Sunday, April 19 |
|
Time: |
|
3:30pm Eastern Time |
|
Location: |
|
Embassy Suites, Washington DC |
|
Presenter: |
Jonathan Rubin, MD, MBA, Chief Medical Officer |
|
Conference Information: |
www.neurologyinnovation.com |
About Alcobra Ltd.
Alcobra Ltd. is an emerging pharmaceutical company primarily focused on the development and commercialization of a proprietary drug candidate, MDX, to treat cognitive disorders including Attention Deficit Hyperactivity Disorder (ADHD) and Fragile X Syndrome. MDX has completed multiple Phase II studies and a Phase III study in adults with ADHD. The company is conducting separate Phase II trials in pediatric ADHD and in Fragile X Syndrome. For more information please visit the Company's website, www.alcobra-pharma.com, the content of which is not incorporated herein by reference.
CONTACT: U.S. Investor Contacts
LifeSci Advisors, LLC
Michael Rice
646-597-6979
mrice@lifesciadvisors.com
Media Inquiries
Sam Brown, Inc.
Mike Beyer
773-463-4211
mikebeyer@sambrown.com
Israel Investor Contact:
Alcobra Investor Relations
Debbie Kaye
+972-72 2204661
debbie@alcobra-pharma.com
